Market Place
Sourcing Support
Health Canada Issues Recall of IDHIFA (enasidenib mesylate)
08 Jun 2023 //
HEALTH CANADA
Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial
25 Aug 2020 //
BUSINESSWIRE
Bristol Myers Squibb`s targeted AML drug Idhifa fails to extend patients` lives
25 Aug 2020 //
FIERCEPHARMA
Agios, seeking a new strategy, touts positive data and marketing deal
13 Jun 2020 //
BIOPHARMADIVE
Medicare Part D no match for runaway specialty drug costs: study
07 Feb 2019 //
REUTERS
Agios wins FDA nod for targeted AML drug Tibsovo
23 Jul 2018 //
FIERCE PHARMA
Agios scores its second new drug approval, ivosidenib heads to the AML market
21 Jul 2018 //
ENDPTS
After some stinging setbacks question high failure ratE Celgene’s drug pipeline
26 May 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.